Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice
about
HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4HMGB1: endogenous danger signalingHBV pathogenesis in animal models: recent advances on the role of plateletsThe Role of HMGB1 Signaling Pathway in the Development and Progression of Hepatocellular Carcinoma: A ReviewHMGB1 mediates endogenous TLR2 activation and brain tumor regressionKupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitisHigh mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserineLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesAspirin's Active Metabolite Salicylic Acid Targets High Mobility Group Box 1 to Modulate Inflammatory ResponsesThe Anti-hepatitis B Virus Activity of Boehmeria nivea Extract in HBV-viremia SCID MiceHMGB1 cytoplasmic translocation in patients with acute liver failure.TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.High-mobility group protein box-1 and its relevance to cerebral ischemiaThe potential role of HMGB1 release in peritoneal dialysis-related peritonitis.Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in ratsSoluble HMGB1 is a novel adipokine stimulating IL-6 secretion through RAGE receptor in SW872 preadipocyte cell line: contribution to chronic inflammation in fat tissueProtective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in ratsElucidating novel mechanisms of brain injury following subarachnoid hemorrhage: an emerging role for neuroproteomicsThe sterile inflammation in the exacerbation of HBV-associated liver injury.Dendritic cells as danger-recognizing biosensors.Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesotheliomaThe HMGB1 receptor RAGE mediates ischemic brain damage.Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic painMicroglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR-gamma AgonistsSurfactant protein-A inhibits mycoplasma-induced dendritic cell maturation through regulation of HMGB-1 cytokine activityHMGB1: a signal of necrosis.Assessment of the tolerability profile of an ophthalmic solution of 5% glycyrrhizin and copolymer PEG/PPG on healthy volunteers and evaluation of its efficacy in the treatment of moderate to severe blepharitis.Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLEPre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions.Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity.Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.IL-33 and HMGB1 alarmins: sensors of cellular death and their involvement in liver pathology.The immune tolerant phase of chronic HBV infection: new perspectives on an old conceptAge-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation.HBV and the immune response.Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway.Immune Response in Hepatitis B Virus Infection.Mouse Models of Hepatitis B Virus Pathogenesis
P2860
Q24306365-F86E38EE-B19B-4DE5-9D56-B6EFF4F18C89Q24645232-CC2D8FB5-0B61-4632-B49C-873168D95B55Q24672103-FCD4E235-22DB-4A28-B15C-FAFE88CD52BBQ26782281-EB909A1B-34A1-47CE-B148-63471D0E18F5Q27307459-36390A25-9619-40D9-907E-3B864A5E8F28Q27349825-25C23F95-02E0-4AC9-9DC5-38C9C1977018Q28118997-8E3E69B2-20BB-45DD-9097-BEED0B9F5B42Q28395597-DCC5FF45-946D-4623-A6DB-7E29E2AF322DQ28611255-D1446D65-DE5A-4D76-A685-8ED4F8E042C6Q33823928-23363CAF-4BEB-4302-8EDA-14DF04E40448Q33846620-426AB6B1-E871-4F96-8808-AB535FBB3577Q34000194-DFD4A87D-36AD-4206-B279-0635CC8F555DQ34004850-B2CC0431-2C71-4F08-AB23-49883524EC00Q34170847-CEB94461-8FB9-4391-A9EC-5C24DBE17012Q34566252-C0D56692-8E79-4485-8AFF-ABF398AD7CC8Q34591167-44E1A829-C7B7-4C95-B25F-EF29B2266E4DQ35000952-311D4BE3-84F8-4F62-AD99-6A8C011E2A8DQ35110571-99CC3CF7-F848-4B82-A2F1-17CC0715FC2CQ35152170-2EC5DAF8-6EE6-4030-B788-8E11C2E40E0BQ35373060-CA163F72-24F2-489C-96AA-9CAC571989B8Q35790418-FED25352-D415-4DE7-A34D-44C65CECF126Q36074728-ED0713B1-747D-463F-ACF9-780EB3CDFDE8Q36134557-CE0921E4-E350-4D24-92B3-C2D543094DF9Q36167647-3F221AE2-BC91-4838-B805-10798B1C4524Q36369795-D9037246-0E89-4165-9C44-B82CAB017B03Q36731548-10DA4D70-8328-46BC-BC24-213835280C00Q36802145-6FF33988-667B-4CBC-B1CB-D8C5559D71ADQ36827934-B1C579A9-5621-4C33-AF9E-42C2DB7370A5Q37015100-42BA2611-9F06-4E8C-B64B-C3FA022E01FEQ37019629-E1F5934C-E8F5-41F0-BC43-97EAD9A405C4Q37216851-3558B0BB-0129-40F6-AB0C-C9F598528F41Q37357090-979E484B-D094-4C0A-8169-D901B6373F24Q37403279-799020AC-0A58-47C9-8833-A7BBD403B62CQ38005217-981A8043-9490-43C5-AFD8-2E63E20F3B0DQ38245181-6155F9FA-B607-433E-99F4-4489FBF40C46Q38258081-C3A539C7-7D3F-4F7D-806C-722B73B17397Q38295864-C610EB73-70C5-4090-AF82-F2CB7A79180EQ38465111-1850A6C5-A198-49E8-AC49-8C79A501FBECQ38541811-FFFBDDE3-0ABB-4198-BCC4-99FB4B909FB1Q38570421-A68D8F3D-35F3-4940-8E92-FDFA1A5CF846
P2860
Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Treatment with HMGB1 inhibitor ...... disease in HBV transgenic mice
@ast
Treatment with HMGB1 inhibitor ...... disease in HBV transgenic mice
@en
Treatment with HMGB1 inhibitor ...... disease in HBV transgenic mice
@nl
type
label
Treatment with HMGB1 inhibitor ...... disease in HBV transgenic mice
@ast
Treatment with HMGB1 inhibitor ...... disease in HBV transgenic mice
@en
Treatment with HMGB1 inhibitor ...... disease in HBV transgenic mice
@nl
prefLabel
Treatment with HMGB1 inhibitor ...... disease in HBV transgenic mice
@ast
Treatment with HMGB1 inhibitor ...... disease in HBV transgenic mice
@en
Treatment with HMGB1 inhibitor ...... disease in HBV transgenic mice
@nl
P50
P356
P1476
Treatment with HMGB1 inhibitor ...... disease in HBV transgenic mice
@en
P2093
Marco E Bianchi
P356
10.1189/JLB.0306173
P407
P577
2007-01-01T00:00:00Z